Keryx Biopharmaceuticals Company Profile (NASDAQ:KERX)

Analyst Ratings

Consensus Ratings for Keryx Biopharmaceuticals (NASDAQ:KERX) (?)
Ratings Breakdown: 2 Sell Rating(s), 4 Hold Rating(s), 7 Buy Rating(s)
Consensus Rating:Hold (Score: 2.38)
Consensus Price Target: $9.44 (27.25% upside)

Analysts' Ratings History for Keryx Biopharmaceuticals (NASDAQ:KERX)
Show:
DateFirmActionRatingPrice TargetActions
7/8/2016Maxim GroupReiterated RatingBuy$7.00 -> $9.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
5/17/2016FBR & CoReiterated RatingOutperform$13.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
4/30/2016Morgan StanleyReiterated RatingHoldView Rating Details  Tweet This Rating  Share This Rating on StockTwits
4/30/2016Cowen and CompanyReiterated RatingHoldView Rating Details  Tweet This Rating  Share This Rating on StockTwits
3/29/2016BTIG ResearchReiterated RatingSell$2.50View Rating Details  Tweet This Rating  Share This Rating on StockTwits
3/9/2016JMP SecuritiesLower Price TargetMarket Outperform$19.00 -> $16.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
2/26/2016Brean CapitalReiterated RatingBuy$18.00 -> $10.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
2/26/2016Stifel NicolausBoost Price TargetBuy$9.00 -> $10.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
2/26/2016Raymond James Financial Inc.UpgradeMarket Perform -> Outperform$6.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
2/26/2016JPMorgan Chase & Co.DowngradeOverweight -> NeutralView Rating Details  Tweet This Rating  Share This Rating on StockTwits
2/19/2016Citigroup Inc.Lower Price Target$2.50 -> $1.80View Rating Details  Tweet This Rating  Share This Rating on StockTwits
8/10/2015Roth CapitalDowngradeBuy -> Neutral$11.00 -> $6.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
8/7/2015MLV & Co.Reiterated RatingBuy$25.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
5/6/2015MizuhoLower Price TargetBuy$25.00 -> $21.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
3/20/2015Oppenheimer Holdings Inc.Lower Price TargetOutperform$22.00 -> $18.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
(Data available from 7/24/2014 forward)

Earnings

Earnings History for Keryx Biopharmaceuticals (NASDAQ:KERX)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallActions
8/3/2016        
4/28/2016Q116($0.26)($0.39)$6.63 million$6.80 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
2/25/2016Q415($0.25)($0.36)$5.68 million$5.80 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
10/29/2015($0.25)($0.29)$3.91 million$4.21 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
8/5/2015Q215($0.26)($0.26)$2.86 million$2.50 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
5/4/2015Q115($0.30)($0.28)$2.45 million$1.20 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
2/27/2015Q414($0.38)($0.44)$1.39 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/6/2014Q314($0.27)($0.38)$0.26 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
8/7/2014Q214($0.25)($0.24)$0.28 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
5/8/2014Q114($0.08)($0.15)$9.91 million$10.00 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
3/12/2014Q413($0.16)($0.21)$2.22 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/5/2013Q313($0.11)($0.19)$2.22 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
8/1/2013Q2 2013($0.10)($0.14)ViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
5/7/2013Q1 2013($0.01)($0.03)$5.83 million$7.00 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
3/12/2013Q4 2012($0.08)($0.09)ViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/7/2012Q312($0.07)($0.08)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
8/7/2012($0.09)($0.02)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
5/8/2012($0.12)($0.13)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
2/29/2012($0.14)($0.12)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
8/8/2011($0.03)($0.05)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Keryx Biopharmaceuticals (NASDAQ:KERX)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20161($0.23)($0.23)($0.23)
Q2 20161($0.21)($0.21)($0.21)
Q3 20161($0.19)($0.19)($0.19)
Q4 20161($0.18)($0.18)($0.18)
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Keryx Biopharmaceuticals (NASDAQ:KERX)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for Keryx Biopharmaceuticals (NASDAQ:KERX)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionActions
7/15/2016Brian AdamsVPSell1,083$7.01$7,591.83View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
7/5/2016Brian AdamsVPSell660$6.66$4,395.60View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
7/5/2016Greg MadisonCEOSell936$6.66$6,233.76View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/9/2016Greg MadisonCEOSell1,873$5.42$10,151.66View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
4/25/2016John F NeylanInsiderSell4,766$5.21$24,830.86View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
4/15/2016Brian AdamsVPSell1,060$5.05$5,353.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
4/5/2016Brian AdamsVPSell759$4.50$3,415.50View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
4/5/2016Greg MadisonCEOSell1,078$4.50$4,851.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
2/9/2016Greg MadisonCEOSell1,938$3.23$6,259.74View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
1/15/2016Brian AdamsVPSell1,322$3.30$4,362.60View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
1/6/2016Brian AdamsVPSell3,004$5.16$15,500.64View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
1/6/2016Greg MadisonCEOSell4,261$4.83$20,580.63View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
11/4/2015Scott A. HolmesCFOBuy5,000$5.33$26,650.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
10/15/2015Brian AdamsVPSell1,011$4.01$4,054.11View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/21/2015Scott A HolmesCFOBuy5,000$5.72$28,600.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
7/15/2015Brian AdamsVPSell1,086$9.99$10,849.14View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
7/6/2015James F Oliviero IIICFOSell1,943$9.61$18,672.23View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/6/2015Michael P TarnokDirectorBuy10,000$9.73$97,300.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
4/15/2015Brian AdamsVPSell4,320$12.40$53,568.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
4/6/2015James F Oliviero IIICFOSell1,878$11.68$21,935.04View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
4/6/2015Ron BentsurCEOSell1,592$11.68$18,594.56View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/6/2015Greg MadisonCOOBuy6,380$12.53$79,941.40View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
2/9/2015Greg MadisonCOOSell6,759$10.95$74,011.05View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
1/5/2015James F Oliviero IIICFOSell5,604$13.79$77,279.16View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
1/5/2015Ron BentsurCEOSell5,574$13.79$76,865.46View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/30/2014Ron BentsurCEOSell200,000$14.11$2,822,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/29/2014Ron BentsurCEOSell338,977$13.98$4,738,898.46View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
10/6/2014Ron BentsurCEOSell70,838$15.88$1,124,907.44View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
10/3/2014James F Oliviero IIICFOSell2,694$16.14$43,481.16View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/12/2014Ron BentsurCEOSell50,000$14.24$712,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/8/2014James F Oliviero IIICFOSell144,237$15.88$2,290,483.56View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
7/7/2014James F Oliviero IIICFOSell2,054$15.75$32,350.50View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
7/7/2014Ron BentsurCEOSell1,788$15.75$28,161.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
4/3/2014James Oliviero IIICFOSell2,087$16.46$34,352.02View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
4/3/2014Ron BentsurCEOSell1,816$16.46$29,891.36View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/21/2014James Oliviero IIICFOSell292,483$15.14$4,428,192.62View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
1/3/2014James Oliviero IIICFOSell6,309$12.57$79,304.13View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
1/3/2014Ron BentsurCEOSell5,257$12.57$66,080.49View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/30/2013James Oliviero IIICFOSell109,500$12.64$1,384,080.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
10/3/2013James Oliviero IIICFOSell1,475$10.25$15,118.75View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
10/3/2013Ron BentsurCEOSell2,505$10.25$25,676.25View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
7/5/2013James F Oliviero IIICFOSell1,438$7.95$11,432.10View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
7/5/2013Ron BentsurCEOSell2,440$7.95$19,398.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/13/2013James F Oliviero IIICFOSell29,363$8.34$244,887.42View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
10/3/2012James F Oliviero IIICFOSell4,973$2.72$13,526.56View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
(Data available from 1/1/2013 forward)

Headlines

Latest Headlines for Keryx Biopharmaceuticals (NASDAQ:KERX)
DateHeadline
07/23/16 08:48 AMIs $13 Price Target Attainable For Keryx Biopharmaceuticals, Inc. (NASDAQ:KERX)? - Investor Newswire
07/23/16 08:48 AMThe Insider Activity Don't Lie: Keryx Biopharmaceuticals Inc. (NASDAQ:KERX) - Review Fortune
07/22/16 04:46 PMKeryx Biopharmaceuticals, Inc. (NASDAQ:KERX) Expected To Post Sales Of $468.403 - Investor Newswire
07/20/16 02:55 PMEquity Roundup: Stock Performance Focus on Keryx Biopharmaceuticals, Inc. (NASDAQ:KERX) - Press Telegraph
07/20/16 02:55 PMShares Jumping Higher in Session: Keryx Biopharmaceuticals Inc. (NASDAQ:KERX) - TGP
07/20/16 02:55 PMActive biotech company shares in the news: Keryx Biopharmaceuticals (KERX), Geron (NASDAQ:GERN) - The Voice Registrar
07/19/16 08:53 AMWill Keryx Biopharmaceuticals (KERX) Continue to Surge Higher? -
07/17/16 04:22 PMShares Moving Down on the Week: Keryx Biopharmaceuticals Inc. (NASDAQ:KERX) - Engelwood Daily
07/17/16 04:22 PMAnalysts: Keryx Biopharmaceuticals Inc. (NASDAQ:KERX) stock is worth $9.44 - Review Fortune
07/16/16 08:11 AMKeryx Biopharmaceuticals, Inc. (NASDAQ:KERX) Yearly Sales Target At $468.403 - Investor Newswire
07/16/16 08:11 AMKeryx Biopharmaceuticals, Inc. (KERX) Updated Price Targets - FTSE News
07/16/16 08:11 AMStrong Sell Calls For Keryx Biopharmaceuticals, Inc. (NASDAQ:KERX) At 0 - Investor Newswire
07/15/16 08:47 AMKeryx Biopharmaceuticals Inc Realized Volatility Hits Extreme Level - CML News
07/14/16 05:00 PMRecent Analysts Rating Overview: Pfizer, Inc. (NYSE:PFE) , Keryx Biopharmaceuticals, Inc. (NASDAQ:KERX) - Street Updates
07/14/16 05:00 PMAnalyst Target and Average Rating Watch: Keryx Biopharmaceuticals, Inc. (NASDAQ:KERX) - Press Telegraph
07/13/16 07:48 AMHot Stock seeking Investors: Keryx Biopharmaceuticals Inc. (NASDAQ:KERX) - News Oracle
07/12/16 09:14 AMActive biotech company shares in the news: Keryx Biopharmaceuticals (KERX), Celldex Therapeutics (NASDAQ:CLDX) - The Voice Registrar
07/11/16 05:19 AM[$$] Keryx Stock Seen Reaching $9 -
07/09/16 08:11 AMKeryx Biopharmaceuticals Inc. (KERX) Jumps 5.07% on July 08 - Equities.com
07/08/16 04:56 PMKeryx Biopharmaceuticals, Inc. (NASDAQ:KERX) Expected To Post Sales Of $451.502 - Investor Newswire
07/08/16 04:56 PMIs $13 Within Reach For Keryx Biopharmaceuticals, Inc. (NASDAQ:KERX)? - Investor Newswire
07/08/16 07:43 AMCan Keryx Biopharmaceuticals, Inc. (NASDAQ:KERX) Improve on the Earnings Front? - Engelwood Daily
07/08/16 07:43 AMCompany Stock Focus for Keryx Biopharmaceuticals, Inc. (NASDAQ:KERX): Which Way Will Shares Head? - Press Telegraph
07/08/16 07:43 AMKeryx Biopharmaceuticals Inc. Stock Momentum Hits Strength - CML News
07/08/16 07:43 AMBroker Outlook For Keryx Biopharmaceuticals, Inc. (KERX) - Fiscal Standard
07/06/16 01:32 PMETF’s with exposure to Keryx Biopharmaceuticals, Inc. : July 6, 2016 -
07/03/16 04:23 PMKeryx Biopharmaceuticals, Inc. (KERX) Current Analyst Ratings - Fiscal Standard
07/01/16 07:38 AMRecently Issued Stock Ratings For Keryx Biopharmaceuticals, Inc. (KERX) - Fiscal Standard
07/01/16 07:38 AMKeryx Biopharmaceuticals (KERX) Is Weak On High Volume Today - TheStreet.com
06/30/16 07:41 AM4 Swing Trades To Watch: AQMS, BCOR, KERX, MVDN
06/28/16 04:44 PMHC Stocks Reports: Minerva Neurosciences Inc (NASDAQ:NERV), Keryx Biopharmaceuticals (NASDAQ:KERX) - share market updates (press release)
06/28/16 09:43 AMStock Update (NASDAQ:KERX): Douglas Jermasek to Join Keryx Biopharmaceuticals as Vice President, Marketing and ... - Smarter Analyst
06/27/16 07:21 AMDouglas Jermasek to Join Keryx Biopharmaceuticals as Vice President, Marketing and Strategy - [at noodls] - BOSTON, June 27, 2016 (GLOBE NEWSWIRE) -- Keryx Biopharmaceuticals, Inc. (Nasdaq:KERX), a biopharmaceutical company focused on bringing innovative medicines to people with renal disease, today announced ...
06/24/16 04:48 PMStrong Sell Calls Recommendations For Keryx Biopharmaceuticals, Inc. (NASDAQ:KERX) At 0 - Investor Newswire
06/24/16 04:48 PMPrice Target Update on Keryx Biopharmaceuticals (NASDAQ:KERX) - Trade Calls
06/24/16 07:27 AMKeryx Biopharmaceuticals Incorporated (NASDAQ:KERX) Sellers Covered 1.36% of Their Shorts - Press Telegraph
06/24/16 07:27 AMKeryx Biopharmaceuticals, Inc. (NASDAQ:KERX) Earnings Glance and Target Price Review - Engelwood Daily
06/24/16 06:22 AMKeryx Biopharmaceuticals Has Gained 19.8% So Far in 2016 -- Here's Why -
06/22/16 08:01 PMAmpliPhi Biosciences Corporation (NYSEMKT:APHB) Decreased -2.29%: Keryx Biopharmaceuticals Inc. (NASDAQ ... - KC Register
06/22/16 08:01 PMKeryx Biopharmaceuticals Inc. (NasdaqCM:KERX) Stock Momentum Hits Strength - CML News
06/22/16 08:01 PMKeryx Biopharmaceuticals (NASDAQ:KERX) Analyst Rating Consensus - TheFounders Daily
06/22/16 08:01 PMCompany Update (NASDAQ:KERX): Keryx Biopharmaceuticals Appoints Two New Board Members - Smarter Analyst
06/21/16 04:20 PMKERYX BIOPHARMACEUTICALS INC Files SEC form 8-K, Change in Directors or Principal Officers, Other Events -
06/20/16 07:59 AMStrong Buy Calls Count For Keryx Biopharmaceuticals, Inc. (NASDAQ:KERX) At 6 - Investor Newswire
06/17/16 07:35 AMTake a look at Price Moves: Keryx Biopharmaceuticals, Inc. (NASDAQ:KERX) , LDR Holding Corporation (NASDAQ ... - Street Updates
06/14/16 07:39 AMKeryx Biopharmaceuticals to Present at JMP’s Life Science Conference on Tuesday, June 21 - [at noodls] - BOSTON, June 14, 2016 (GLOBE NEWSWIRE) -- Keryx Biopharmaceuticals, Inc, (NASDAQ:KERX), a biopharmaceutical company focused on bringing innovative medicines to people with renal disease, today announced ...
06/13/16 07:39 AMHC Stocks Highlights: Keryx Biopharmaceuticals (NASDAQ:KERX), NuVasive, Inc. (NASDAQ:NUVA) - share market updates (press release)
06/11/16 07:37 AMEarnings Overview of the Stocks: Keryx Biopharmaceuticals Inc. (NASDAQ:KERX), The Valspar Corporation (NYSE:VAL) - Beacon Chronicle
06/07/16 04:59 PMHave a look at Price Moves: Keryx Biopharmaceuticals, Inc. (NASDAQ:KERX) , Vanda Pharmaceuticals Inc. (NASDAQ ... - Street Updates
06/06/16 04:43 PMHealthcare Laggards: Celldex Therapeutics, Inc. (NASDAQ:CLDX), Keryx Biopharmaceuticals Inc. (NASDAQ:KERX ... - KC Register

Social

About Keryx Biopharmaceuticals

Keryx Biopharmaceuticals logoKeryx Biopharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on the development of products for the treatment of renal diseases. The Company's product Auryxia (ferric citrate), also known as Riona in Japan and Fexeric in Europe, is an oral, absorbable iron-based compound, which is indicated for the control of serum phosphorus levels in patients with chronic kidney disease (CKD), on dialysis. The Company operates through the products segment. Auryxia can bind to phosphate in the gastrointestinal tract and form non-absorbable complexes to reduce intestinal absorption and aid in the management of hyperphosphatemia in patients with CKD. The adverse events for Auryxia treated patients were gastrointestinal-related, including diarrhea, nausea, constipation, vomiting and cough. The Company focuses on Keryx Patient Plus program to assist with patient accessibility to Auryxia.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology
  • Sub-Industry: Biotechnology
  • Exchange: NASDAQ
  • Symbol: KERX
  • CUSIP: 49251510
Key Metrics:
  • Previous Close: $7.42
  • 50 Day Moving Average: $6.56
  • 200 Day Moving Average: $5.06
  • P/E Ratio: N/A
  • P/E Growth: -0.07
  • Market Cap: $785.18M
  • Beta: 4.03
  • Current Year EPS Consensus Estimate: $-0.97 EPS
  • Next Year EPS Consensus Estimate: $-0.31 EPS
Additional Links:
Keryx Biopharmaceuticals (NASDAQ:KERX) Chart for Sunday, July, 24, 2016